Cost-effectiveness analysis of treatments for chronic disease: Using R to incorporate time dependency of treatment response

Medical Decision Making

Volumn 25, Issue 5, 2005, Pages 511-519

  Hawkins, Neil ^a   Sculpher, Mark ^a   Epstein, David ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Cost effectiveness analysis; Markov models; Time dependency

Indexed keywords

CHRONIC DISEASE; COST EFFECTIVENESS ANALYSIS; EPILEPSY; HEALTH CARE COST; MEDICAL DECISION MAKING; PROBABILITY; REVIEW; RISK ASSESSMENT; SIMULATION; STATISTICAL MODEL; TREATMENT OUTCOME;

CHRONIC DISEASE; COST-BENEFIT ANALYSIS; EVIDENCE-BASED MEDICINE; HUMANS; PATIENT SIMULATION; PROBABILITY; TREATMENT OUTCOME;

EID: 25644440063     PISSN: 0272989X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0272989X05280562     Document Type: Review

References (16)

1. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making. 1983;3:419-58.
2. Sonnenberg FA, Beck JR. Markov models in medical decision making. Med Dec Making. 1993;13:322-38.
3. Briggs A, Sculpher MJ. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 1998;13:397-409.
4. Billingham LJ, Abrams KR, Jones DR. Methods for the analysis of quality-of-life and survival data in health technology assessment. Health Technol Assessment. 1999;3:1-152.
5. Briggs A, Sculpher M, Britton A, Murray D, Fitzpatrick R. The costs and benefits of primary total hip replacement: how likely are new prostheses to be cost-effective? Int J Technol Assessment Health Care. 1998;14:743-61.
6. Venables WN, Smith DM, the R Development Core Team. An introduction to R: a programming environment for data analysis and graphics (Version 2.0.1). Available from: http://cran.r-project.org/ doc/manuals/R-intro.pdf
7. Wilby J, Kainth K, Hawkins N, et al. A Rapid and Systematic Review of the Clinical Effectiveness, Tolerability and Cost Effectiveness of Newer Drugs for Epilepsy in Adults. London: National Institute for Clinical Excellence; 2003. Available from: www.nice.org.uk
8. Hawkins N, Epstein D, Drummond M, et al. Assessing the cost-effectiveness of new pharmaceuticals in epilepsy in adults: the results of a probabilistic decision model. Med Decis Making. Submitted for publication.
9. Abbott Laboratories. An Open-Label Extension Study of Tiagabine HCl in the Treatment of Patients with Partial Seizures. Abbott Park, IL: Abbott Laboratories; 1998.
10. Lhatoo SD, Sander JWAS, Shorvon SD. The dynamics of drug treatment in epilepsy: an observational study in an unselected population based cohort with newly diagnosed epilepsy followed up prospectively over 11-14 years. J Neurol Neurosurg Psychiatry. 2001;71:632-7.
11. Stinnett A, Paltiel AD. Estimating CE ratios under second-order uncertainty: the mean ratio versus the ratio of means. Med Decis Making. 1997;17:483-9.
12. Briggs AH, Goeree R, Blackhouse G, O'Brien BJ. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making. 2002;22:290-308.
13. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001;10:779-89.
14. Stevenson MD, Oakley J, Chilcott JB. Gaussian process modelling in conjunction with individual patient simulation modelling: a case study describing the calculation of cost-effectiveness ratios for the treatment of established osteoporosis. Med Decis Making. 2004;24:89-100.
15. Claxton K, Posnett J. An economic approach to clinical trial design and research priority-setting. Health Econ. 1996;5:513-24.
16. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ. 1999;18:342-64.